Sequence: d(P-thio)([(5′ξ)-2′,5′-anhydro-6′-deoxy-4′-C-(hydroxymethyl)-α-L-lyxo-hexofurano]m5C-(3′→4′)-[(5′ξ)-2′,5′-anhydro-6′-deoxy-4′-C-(hydroxymethyl)-α-L-lyxo-hexofurano]m5U-(3′→4′)-[(5′ξ)-2′,5′-anhydro-6′-deoxy-4′-C-(hydroxymethyl)-α-L-lyxo-hexofurano]A-T-T-T-G-G-A-T-G-T-m5C-(3′→4′)-[(5′ξ)-2′,5′-anhydro-6′-deoxy-4′-C-(hydroxymethyl)-α-L-lyxo-hexofurano]A-(3′→4′)-[(5′ξ)-2′,5′-anhydro-6′-deoxy-4′-C-(hydroxymethyl)-α-L-lyxo-hexofurano]G-(3′→4′)-[(5′ξ)-2′,5′-anhydro-6′-deoxy-4′-C-(hydroxymethyl)-α-L-lyxo-hexofurano]m5C).
Danvatirsen is an antisense oligonucleotide targeting STAT3 with potential antitumor activity. Danvatirsen binds to STAT3 mRNA, thereby inhibiting translation of the transcript. Suppression of STAT3 expression induces tumor cell apoptosis and decreases tumor cell growth.
[1]. Hong D, Kurzrock R, Kim Y, et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med. 2015;7(314):314ra185. [2]. Reilley MJ, McCoon P, Cook C, et al. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. J Immunother Cancer. 2018;6(1):119. [3]. Odate S, Veschi V, Yan S, Lam N, Woessner R, Thiele CJ. Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity. Clin Cancer Res. 2017;23(7):1771-1784.
[4]. Shastri A, Choudhary G, Teixeira M, et al. Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells. J Clin Invest. 2018;128(12):5479-5488.